A Phase 1 interventional study of Obinutuzumab and Prednisone in Lymphoma, Non-Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment
Drug: Venetoclax · Diagnostic test: EKG · Procedure: Bone marrow aspiration · Procedure: Bone marrow biopsy · Diagnostic test: CT · Diagnostic test: MRI · Diagnostic test: PET · Procedure: Tumor tissue/Biopsy · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Polatuzumab
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Lymphoma, Non-Hodgkin by National Cancer Institute (NCI) — 10 open to participants now, 22 under way, none of them phase 3. Lymphoma, Non-Hodgkin · National Cancer Institute (NCI).
Among the 136 studies in Lymphoma, Non-Hodgkin by National Cancer Institute (NCI), this one is the 38th largest by enrollment of the 113 interventional ones that give a count, is one of 2 that started in 2021, is one of 67 in phase 1, reaches primary completion later than 9 of the 17 other live ones, and was the 131st registered.
2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →10 of the 136 studies in Lymphoma, Non-Hodgkin by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 3–39
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 79 · Phase 2 50 · Phase 3 1
First in 1989; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is above the median of 40 across 1,884 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 35 across the 113 interventional studies, 1,279 across the 16 observational. Of the 112 that completed or were terminated, 35 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
4 of the studies in Lymphoma, Non-Hodgkin by National Cancer Institute (NCI) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05627245National Cancer Institute (NCI)Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | 2027-06-01 |
| NCT05442515National Cancer Institute (NCI)CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | 2027-07-01 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
| NCT04002947National Cancer Institute (NCI)Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | 2027-10-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 136 studies in Lymphoma, Non-Hodgkin by National Cancer Institute (NCI), from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy and treatment is aimed at controlling symptoms and achieving a durable remission. Researchers want to see if a combination of drugs can help patients with both aggressive and indolent B-cell lymphomas.
Objective:
To learn if it is safe and effective to give polatuzumab along with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to people with certain B-cell lymphomas.
Eligibility:
Adults ages 18 and older with relapsed and/or refractory B-cell lymphoma who have had at least one prior cancer treatment.
Design:
Participants will be screened with:
Medical history
Physical exam
Assessment of how they do their daily activities
Blood and urine tests
Heart function test
Tissue biopsy (if needed)
Body imaging scans (may get a contrast agent through an intravenous (IV) catheter)
Participants will have a bone marrow aspiration and/or biopsy. A needle will be put into the hipbone. Bone marrow will be removed.
Participants may give blood, tissue, saliva, or cheek swab samples. They may have optional biopsies.
Screening tests will be repeated during the study.
Treatment will be given for up to 6 cycles. Each cycle lasts 21 days.
Participants will take venetoclax and prednisone tablets by mouth. They will take ibrutinib and lenalidomide capsules by mouth. They will get obinutuzumab and polatuzumab by IV infusion. They will keep a medicine diary.
Participants will visit the clinic 30 days after treatment ends. They will have follow-up visits for 5 years. If needed, they can visit their local doctor instead. They may be contacted by phone, mail, etc., for the rest of their life....
Background:
Objectives:
Diffuse large B-cell lymphoma (DLBCL)
Eligibility:
Design:
DLBCL patients in a dose expansion at the MTD as well as to allow for the possibility of a few screen failures and inevaluable subjects, the accrual ceiling will be set at 55 patients.
2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
This study's enrollment of 49 is above the median of 40 across 1,884 interventional studies indexed under Lymphoma, Non-Hodgkin.
Browse Lymphoma, Non-Hodgkin studies →National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Nov 12, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohorts 1 and 2:
Indolent B-cell lymphoma: with the following exceptions:
Cohort 3:
-Non-germinal center B-cell-like (Non-GCB) DLBCL: includes DLBCL not otherwise specified (NOS) and subtypes, transformed lymphoma, T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), as well as high-grade B-cell lymphoma with MYC and/or BCL6 rearrangement(s).
NOTE: Patients with known active central nervous system (CNS) lymphoma are not eligible.
Relapsed and/or refractory disease after at least 1 prior treatment regimen, as follows:
NOTE: Lesions that have been irradiated cannot be included in the tumor assessment unless unequivocal tumor progression has been documented in these lesions after radiation therapy.
-Age >=18 years
NOTE: Because no dosing or adverse event data are currently available on the use of polatuzumab in combination with venetoclax, ibrutinib, obinutuzumab, prednisone and Revlimid(R) in patients \<18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
Adequate organ and marrow function as defined below unless dysfunction is secondary to lymphoma:
NOTE: Creatinine clearance (Cr Cl) will be calculated with the use of the 24-hour creatinine clearance or estimated (eGRF) in the clinical lab
Red blood cell (RBC) transfusions and use of granulocyte colony-stimulating factor (G-CSF) will be allowed in order to meet eligibility parameters.
Immune-modulating drugs (IMiDs) including Revlimid(R) are known to be teratogenic and potential embryo-fetal harm can be seen with use of polatuzumab, venetoclax and ibrutinib. The effects of obinutuzumab on the developing human fetus is unknown. For these reasons, individuals of and individuals able to father a child must agree to use adequate as described below.
For individuals of childbearing potential:
For individuals able to father a child:
Contraception Requirements
Time frame/Study Drug (Pre-Treatment/During Treatment) - Individuals of childbearing potential (Time frame prior to/during dosing) / Individuals able to father a child (Time frame prior to/during dosing):
---All drugs; Begins 28 days prior to treatment; Begins on day 1
Time frame/Study Drug (Post-Treatment) - Individuals of childbearing potential (Time frame after the last dose) / Individuals able to father a child (Time frame after the last dose):
EXCLUSION CRITERIA:
The following restrictions apply to current or prior anti-cancer treatment, prior to the first dose of study drug:
Patients requiring the following agents to the first dose of venetoclax or ibrutinib are excluded, as noted:
NOTE: Moderate CYP3A inhibitors and inducers should be used with caution and an alternative medication used, whenever possible.
Uncontrolled intercurrent illness including, but not limited to the following that may limit interpretation of results or that could increase risk to the patient at the discretion of the investigator:
history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis; as well as active infection with virus (HBV) or virus (HCV):
History of other active that could affect compliance with the protocol or interpretation of results
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Venetoclax by mouth (PO) at escalating doses (2 dose levels) on days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg intravenous (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at escalating doses (2 dose levels) on day 2 of each 21-day cycle (maximum 6 cycles) to determine maximum tolerated dose (MTD) of polatuzumab and venetoclax.
Biological: Obinutuzumab · Drug: Prednisone · Drug: Revlimid · Biological: Polatuzumab · Drug: Ibrutinib · Drug: Venetoclax · Diagnostic Test: EKG · Procedure: Bone marrow aspiration · Procedure: Bone marrow biopsy · Diagnostic Test: CT · Diagnostic Test: MRI · Diagnostic Test: PET · Procedure: Tumor tissue/Biopsy · Drug: Acetaminophen · Drug: Diphenhydramine
Venetoclax by mouth (PO) at the maximum tolerated dose (MTD) days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg intravenous (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at the MTD of each 21-day cycle (maximum 6 cycles)
Biological: Obinutuzumab · Drug: Prednisone · Drug: Revlimid · Drug: Ibrutinib · Diagnostic Test: EKG · Procedure: Bone marrow aspiration · Procedure: Bone marrow biopsy · Diagnostic Test: CT · Diagnostic Test: MRI · Diagnostic Test: PET · Procedure: Tumor tissue/Biopsy · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Venetoclax · Drug: Polatuzumab
Administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.
Also known as: Gazyva
Administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.
Also known as: Deltasone, Sterapred
Administered orally, days 1-14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.
Also known as: Lenalidomide
Administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level) in Arm 1 every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity. Also given at the MTD in Arm 2 (Dose Expansion).
Also known as: Polivy
Administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.
Also known as: Imbruvica
Administered orally, days 2-14, at varying doses of 600 mg - 800 mg (based upon assigned dose level) in Arm 1 every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity. Also given at the maximum tolerated dose (MTD) in Arm 2 (Dose Expansion).
Also known as: Venclexta
Screening
Also known as: Electrocardiogram
Baseline, end of treatment/disease progression, and in follow-up as clinically indicated.
Also known as: BM aspiration
Baseline, end of treatment/disease progression, and in follow-up as clinically indicated.
Also known as: BM Bx
Screening, Cycle 1/Day1, pre-cycle 3 \& 5, disease progression/end of treatment, and post treatment follow-up.
Also known as: Computed tomography
MRI (optional) is an allowed alternative to CT per protocol. Screening, Cycle 1/Day1 (pre-cycle 3 \& 5), disease progression/end of treatment, and post treatment follow-up.
Also known as: Magnetic resonance imaging
Baseline, end of treatment, and at progressive disease.
Also known as: Positron emission tomography
Baseline, disease progression/end of treatment and disease progression post treatment follow-up.
Also known as: Tumor tissue/Bx
Premedication 30-60 minutes before Obinutuzumab.
Also known as: Tylenol, Paracetamol, Panadol, Mapap, APAP
Premedication 30-60 minutes before Obinutuzumab.
Also known as: Diphenhydramine HCL, Diphenhydramine hydrochloride, Benadryl
Administered orally, days 2-14, at the maximum tolerated dose (MTD) every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.
Also known as: Venclexta
Administered intravenously, on day 2, at the maximum tolerated dose (MTD) every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity.
Also known as: Polivy
Dose Escalation: Number of Grade 3, 4 and/or 5 Dose-limiting (DLT) Adverse Events at Each Dose Level With Type
Number, type and grade of adverse events at each dose level was assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment.
Time frame: 21 days
Maximum Tolerated Dose (MTD) of Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
MTD is defined as the dose level at which no more than 1 of up to 6 participants experience a dose-limiting toxicity, or the dose level below that at which at least 2 (of ≤6) participants have a DLT. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment. Such as Grade 3 nausea with maximum medical supportive care and persisting ≤7 days; Grade 3 vomiting or diarrhea f the participant does not require total parenteral nutrition (TPN), tube feeding, or hospitalization, and the toxicity improves to \< grade 3 within ≤3 days; Grade 3 fatigue persisting ≤7 days; Grade 3 fever or infection; Grade 3 infusion related reaction; Grade 3 febrile neutropenia; Grade 3 or Grade 4 neutropenia, Grade 3 thrombocytopenia not associated with grade 2 or greater bleeding; Grade 3 anemia persisting ≤7 days; and treatment delay of Cycle 2 for ≤7 days for hematologic toxicity.
Time frame: 21 Days (Cycle 1)
Maximum Tolerated Dose (MTD) of Venetoclax in Relapsed/Refractory B-cell Lymphoma
MTD is defined as the dose level at which no more than 1 of up to 6 participants experience a dose-limiting toxicity, or the dose level below that at which at least 2 (of ≤6) participants have a DLT. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment. Such as Grade 3 nausea with maximum medical supportive care and persisting ≤7 days; Grade 3 vomiting or diarrhea f the participant does not require total parenteral nutrition (TPN), tube feeding, or hospitalization, and the toxicity improves to \< grade 3 within ≤3 days; Grade 3 fatigue persisting ≤7 days; Grade 3 fever or infection; Grade 3 infusion related reaction; Grade 3 febrile neutropenia; Grade 3 or Grade 4 neutropenia, Grade 3 thrombocytopenia not associated with grade 2 or greater bleeding; Grade 3 anemia persisting ≤7 days; and treatment delay of Cycle 2 for ≤7 days for hematologic toxicity.
Time frame: 21 Days (Cycle 1)
Overall Response Rate (ORR)
Overall response rate was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter. of a lesion. Partial response is ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir and an increase in LDi or shortest axis perpendicular to the LDi (SDi) from nadir; 0.5 cm for lesions ≤2 cm and 1.0 cm for lesions \>2 cm. Also new or clear progression of pre-existing nonmeasured lesions. ORR was measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.
Time frame: Every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment, up to 18 weeks
Duration of Response
DOR is defined as the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death, assessed every 3-12 months, measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter. Partial response is ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.
Time frame: Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death
Progression-free Survival (PFS)
PFS is defined as the time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first, assessed every 3-12 months measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Disease relapse is Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.
Time frame: Time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first
Event-free Survival (EFS)
EFS is defined as the time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first, assessed every 3-12 months. measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Diseae relapse is Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.
Time frame: Time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first
Overall Survival (OS)
OS is defined as the time from the date of study enrollment until death from any cause, assessed every 3-12 months measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.
Time frame: Time from the date of study enrollment until death from any cause
Complete Response Rate in Non-Germinal Center B-cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) Treated at the Maximum Tolerated Dose (MTD)
Complete response rate is based on Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter of a lesion. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir and an increase in LDi or shortest axis perpendicular to the LDi (SDi) from nadir; 0.5 cm for lesions ≤2 cm and 1.0 cm for lesions \>2 cm. Also new or clear progression of pre-existing nonmeasured lesions. Complete response is measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.
Time frame: Every 42 days for 3 assessments (e.g., every 2 cycles) and/or end of treatment, up to 18 weeks
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Adverse Events were monitored/assessed from the date of first dose of any study drug, through 30 days after the last dose of any study drug, an average of 5.2 months
| Milestone | Participant Consented, Enrolled But Not Treated | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 |
|---|---|---|---|---|---|---|
| Started | 0 | 3 | 6 | 6 | 0 | 0 |
| Completed | 0 | 3 | 6 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Participant Consented, Enrolled But Not Treated | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 |
|---|---|---|---|---|---|---|
| Started | 1 | 0 | 0 | 0 | 8 | 25 |
| Completed | 0 | 0 | 0 | 0 | 8 | 25 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Screen failure | 1 | 0 | 0 | 0 | 0 | 0 |
Number, type and grade of adverse events at each dose level was assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment.
| Adverse events | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 |
|---|---|---|---|
| Grade 4 Thrombocytopenia persisting for >7 days | 0 | 0 | 1 |
| No Grade 3 and 5 Adverse Events That Met DLT Criteria | 0 | 0 | 0 |
MTD is defined as the dose level at which no more than 1 of up to 6 participants experience a dose-limiting toxicity, or the dose level below that at which at least 2 (of ≤6) participants have a DLT. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment. Such as Grade 3 nausea with maximum medical supportive care and persisting ≤7 days; Grade 3 vomiting or diarrhea f the participant does not require total parenteral nutrition (TPN), tube feeding, or hospitalization, and the toxicity improves to \< grade 3 within ≤3 days; Grade 3 fatigue persisting ≤7 days; Grade 3 fever or infection; Grade 3 infusion related reaction; Grade 3 febrile neutropenia; Grade 3 or Grade 4 neutropenia, Grade 3 thrombocytopenia not associated with grade 2 or greater bleeding; Grade 3 anemia persisting ≤7 days; and treatment delay of Cycle 2 for ≤7 days for hematologic toxicity.
| mg/kg | Dose Escalation: All Participants |
|---|---|
| Maximum Tolerated Dose (MTD) of Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | 1.8 |
MTD is defined as the dose level at which no more than 1 of up to 6 participants experience a dose-limiting toxicity, or the dose level below that at which at least 2 (of ≤6) participants have a DLT. A DLT is a grade 3 or higher adverse event at least possibly related to the study agent that occurs within the first 21 days of Cycle 1 of treatment. Such as Grade 3 nausea with maximum medical supportive care and persisting ≤7 days; Grade 3 vomiting or diarrhea f the participant does not require total parenteral nutrition (TPN), tube feeding, or hospitalization, and the toxicity improves to \< grade 3 within ≤3 days; Grade 3 fatigue persisting ≤7 days; Grade 3 fever or infection; Grade 3 infusion related reaction; Grade 3 febrile neutropenia; Grade 3 or Grade 4 neutropenia, Grade 3 thrombocytopenia not associated with grade 2 or greater bleeding; Grade 3 anemia persisting ≤7 days; and treatment delay of Cycle 2 for ≤7 days for hematologic toxicity.
| mg | Dose Escalation: All Participants |
|---|---|
| Maximum Tolerated Dose (MTD) of Venetoclax in Relapsed/Refractory B-cell Lymphoma | 800 |
Overall response rate was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter. of a lesion. Partial response is ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir and an increase in LDi or shortest axis perpendicular to the LDi (SDi) from nadir; 0.5 cm for lesions ≤2 cm and 1.0 cm for lesions \>2 cm. Also new or clear progression of pre-existing nonmeasured lesions. ORR was measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.
| proportion of participants | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 | Total |
|---|---|---|---|---|---|---|
| Complete Response (CR) | 0.67 (0.12 to 0.98) | 0.5 (0.19 to 0.81) | 0.5 (0.19 to 0.81) | 0.5 (0.22 to 0.79) | 0.68 (0.48 to 0.83) | 0.60 (0.46 to 0.73) |
| Partial Response (PR) | 0.00 (0.00 to 0.56) | 0.33 (0.06 to 0.70) | 0.00 (0.00 to 0.39) | 0.38 (0.14 to 0.69) | 0.2 (0.09 to 0.39) | 0.21 (0.12 to 0.34) |
| Stable Disease (SD) | 0.33 (0.02 to 0.88) | 0.17 (0.01 to 0.56) | 0.5 (0.19 to 0.81) | 0.00 (0.00 to 0.32) | 0.04 (0.00 to 0.20) | 0.13 (0.06 to 0.25) |
| Progressive Disease (PD) | 0.00 (0.00 to 0.56) | 0.00 (0.00 to 0.39) | 0.00 (0.00 to 0.47) | 0.13 (0.01 to 0.47) | 0.08 (0.01 to 0.25) | 0.06 (0.02 to 0.17) |
DOR is defined as the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented or death, assessed every 3-12 months, measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter. Partial response is ≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) of up to 6 target measurable nodes and extranodal sites. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.
Results for this outcome have not been posted.
PFS is defined as the time from date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first, assessed every 3-12 months measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Disease relapse is Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.
Results for this outcome have not been posted.
EFS is defined as the time from the date of study enrollment until time of disease relapse, disease progression, alternative therapy for lymphoma given (such as radiation), or death, whichever occurs first, assessed every 3-12 months. measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval. Response was assessed by the Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Diseae relapse is Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir.
Results for this outcome have not been posted.
OS is defined as the time from the date of study enrollment until death from any cause, assessed every 3-12 months measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.
Results for this outcome have not been posted.
Complete response rate is based on Lugano Classification Response Criteria for Non-Hodgkin Lymphoma. Complete response is no extralymphatic sites of disease or new lesions, and target nodes/nodal masses must regress to ≤1.5 cm in longest diameter of a lesion. Progressive disease is progressive metabolic disease. Node or lesion longest transverse diameter of a lesion (LDi) \>1.5 cm and increase by ≥50% from cross product of the LDi and perpendicular diameter (PPD) nadir and an increase in LDi or shortest axis perpendicular to the LDi (SDi) from nadir; 0.5 cm for lesions ≤2 cm and 1.0 cm for lesions \>2 cm. Also new or clear progression of pre-existing nonmeasured lesions. Complete response is measured by the Kaplan Meier method and reported along with a 2-sided 95% confidence interval.
| proportion of participants | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL | Total |
|---|---|---|---|---|
| Complete Response Rate in Non-Germinal Center B-cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) Treated at the Maximum Tolerated Dose (MTD) | 0.75 (0.30 to 0.99) | 0.67 (0.12 to 0.98) | 0.68 (0.48 to 0.83) | 0.69 (0.51 to 0.82) |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
| Participants | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 |
|---|---|---|---|---|---|
| Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 3 | 6 | 6 | 8 | 25 |
Collected over All-Cause Mortality was monitored/assessed, up to 60.0 months. Adverse Events were monitored/assessed from the date of first dose of any study drug, through 30 days after the last dose of any study drug, up to 5.2 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | 4/6 (66.7%) | 3/6 (50%) | 6/6 (100%) |
| Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | 5/8 (62.5%) | 4/8 (50%) | 8/8 (100%) |
| Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 | 9/25 (36%) | 12/25 (48%) | 25/25 (100%) |
| Event | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 |
|---|---|---|---|---|---|
| HypokalemiaMetabolism and nutrition disorders | 1/3 | 0/6 | 0/6 | 0/8 | 1/25 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/6 | 0/6 | 2/8 | 1/25 |
| FeverGeneral disorders and administration site conditions | 0/3 | 1/6 | 1/6 | 1/8 | 2/25 |
| Hepatobiliary disorders - Other, specify: Drug induced liver injuryHepatobiliary disorders | 0/3 | 1/6 | 0/6 | 0/8 | 0/25 |
| COVID-19 InfectionInfections and infestations | 0/3 | 0/6 | 1/6 | 0/8 | 0/25 |
| Skin infectionInfections and infestations | 0/3 | 0/6 | 1/6 | 0/8 | 0/25 |
| Alanine aminotransferase increasedInvestigations | 0/3 | 1/6 | 0/6 | 0/8 | 0/25 |
| Aspartate aminotransferase increasedInvestigations | 0/3 | 1/6 | 0/6 | 0/8 | 0/25 |
| Blood bilirubin increasedInvestigations | 0/3 | 1/6 | 0/6 | 0/8 | 0/25 |
| Thromboembolic eventVascular disorders | 0/3 | 0/6 | 1/6 | 0/8 | 0/25 |
| Event | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 |
|---|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 2/3 | 5/6 | 6/6 | 7/8 | 24/25 |
| Alanine aminotransferase increasedInvestigations | 3/3 | 4/6 | 4/6 | 3/8 | 16/25 |
| Alkaline phosphatase increasedInvestigations | 3/3 | 4/6 | 1/6 | 3/8 | 15/25 |
| Platelet count decreasedInvestigations | 3/3 | 6/6 | 6/6 | 7/8 | 24/25 |
| HypokalemiaMetabolism and nutrition disorders | 3/3 | 6/6 | 6/6 | 7/8 | 25/25 |
| HypomagnesemiaMetabolism and nutrition disorders | 3/3 | 1/6 | 2/6 | 4/8 | 14/25 |
| DiarrheaGastrointestinal disorders | 2/3 | 5/6 | 5/6 | 6/8 | 21/25 |
| NauseaGastrointestinal disorders | 2/3 | 1/6 | 5/6 | 4/8 | 5/25 |
| Blood bilirubin increasedInvestigations | 1/3 | 2/6 | 2/6 | 3/8 | 20/25 |
| Neutrophil count decreasedInvestigations | 1/3 | 2/6 | 4/6 | 6/8 | 19/25 |
All participants consented and enrolled who had data collected are reported in the table.
| Age, Categorical(Participants) | Participant Consented, Enrolled But Not Treated | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 3 | 5 | 5 | 6 | 15 | 35 |
| >=65 years | 0 | 0 | 1 | 1 | 2 | 10 | 14 |
| Age, Continuous(years) | Participant Consented, Enrolled But Not Treated | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 53 | 59 ± 7 | 54.17 ± 14.8 | 51.33 ± 12.53 | 54.63 ± 15.81 | 58.64 ± 14.47 | 56.45 ± 13.79 |
| Sex: Female, Male(Participants) | Participant Consented, Enrolled But Not Treated | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 2 | 1 | 3 | 1 | 7 | 14 |
| Male | 1 | 1 | 5 | 3 | 7 | 18 | 35 |
| Race (NIH/OMB)(Participants) | Participant Consented, Enrolled But Not Treated | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 0 | 1 | 0 | 1 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 1 | 2 | 1 | 7 | 11 |
| White | 1 | 2 | 4 | 2 | 7 | 16 | 32 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Participant Consented, Enrolled But Not Treated | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 1 | 3 | 4 | 6 | 8 | 25 | 47 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Participant Consented, Enrolled But Not Treated | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 | Total |
|---|---|---|---|---|---|---|---|
| United States | 1 | 3 | 6 | 6 | 8 | 25 | 49 |
| Disease Histology(Participants) | Participant Consented, Enrolled But Not Treated | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 1 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 2 | Indolent/Aggressive B-Cell Lymphoma, Cohort 1: Dose Escalation, Arm 1, Dose Level (DL) 3 | Indolent/Aggressive B-Cell Lymphoma, Cohort 2: Dose Expansion, Arm 2, Dose Level (DL) 3 | Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, Cohort 3: Dose Expansion, Arm 2, DL 3 | Total |
|---|---|---|---|---|---|---|---|
| Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma (GCB DLBCL) | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| High-Grade B-Cell Lymphoma, Double-Hit, with B-cell Lymphoma 2 rearrangement (HGBCL-DH-BCL2) | 0 | 2 | 2 | 2 | 5 | 0 | 11 |
| High-Grade B-Cell Lymphoma, Double-Hit, with B-cell Lymphoma 6 rearrangement (HGBCL-DH-BCL6) | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Non-Germinal Center B-cell-like Diffuse Large B-Cell Lymphoma (Non-GCB DLBCL) | 0 | 1 | 3 | 4 | 2 | 19 | 29 |
| T-cell/Histiocyte Rich Large B Cell Lymphoma (THRLBCL) | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP). All collected IPD will be shared with collaborators under the terms of collaborative agreements.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Clinical data will be available during the study and indefinitely. Genomic data will be available once genomic data are uploaded per protocol Genomic Data Sharing (GDS) plan for as long as database is active.
Access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data will be made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.
Ran from Jul 2021 to primary completion in May 2026, 57 months.
Results were first posted in Nov 2026, 6 months after primary completion.
Of 123 non-industry phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 80. This study's 57 months is close to that.
Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.
Completion moved once since we started tracking on Sep 25, 2026: Jun 2031 → May 2031, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Drug: Venetoclax · Diagnostic test: EKG · Procedure: Bone marrow aspiration · Procedure: Bone marrow biopsy · Diagnostic test: CT · Diagnostic test: MRI · Diagnostic test: PET · Procedure: Tumor tissue/Biopsy · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Polatuzumab
Drug: Venetoclax · Diagnostic test: EKG · Procedure: Bone marrow aspiration · Procedure: Bone marrow biopsy · Diagnostic test: CT · Diagnostic test: MRI · Diagnostic test: PET · Procedure: Tumor tissue/Biopsy · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Polatuzumab
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Polatuzumab
National Cancer Institute (NCI) →